Altre lingue Personalis, Inc.

Azioni

PSNL

US71535D1063

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 31/05/2024			Variaz. 5gg	Var. 1 gen.
1,3 ^USD	-0,76%		-2,99%	-38,10%

08/05	Transcript : Personalis, Inc., Q1 2024 Earnings Call, May 08, 2024
08/05	Personalis, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Transcript : Personalis, Inc., Q1 2024 Earnings Call, May 08, 2024	08/05
Personalis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Personalis, Inc. Provides Earnings Guidance for the Second Quarter of 2024	08/05
Personalis, Inc. Revises Earnings Guidance for the Full Year of 2024	08/05
PERSONALIS, INC. : Lake Street persiste à l'achat	30/04
Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring	26/03
PERSONALIS, INC. : Needham & Co. toujours à l'achat	29/02
Transcript : Personalis, Inc., Q4 2023 Earnings Call, Feb 28, 2024	28/02
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	28/02
Personalis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Personalis to Offer ClearNote's Epigenomic Platform in Partnership	30/01
Personalis, Inc. and ClearNote Health, Inc. Announce Partnership to Advance Epigenomic Technology	30/01
Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay	16/01
Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	05/01
Personalis, Tempus Labs to Collaborate on NeXT Personal Dx Detection Test	28/11
Personalis and Tempus Enter into Strategic Collaboration to Advance Cancer Testing	28/11
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform	16/11
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers	16/11
PERSONALIS, INC. : Needham & Co. reste à l'achat	08/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Personalis, Inc.

Azioni

PSNL

US71535D1063

Altre lingue

Filtri